³í¹®) Preclinical and dose-ranging assessment of hESCderived dopaminergic progenitors for a clinical trial on Parkinson’s disease ¿¬¼¼´ë ÀÇ´ë »ý¸®Çб³½Ç ±èµ¿¿í ±³¼ö(»çÁø, ¿¬±¸ Ã¥ÀÓÀÚ)ÆÀ